local US shipping with tracking#
Purity: 98.65%
Form: White Powder
Unit Size: 5 mg/vial
Unit Quantity: 1 Vial
Synonyms: brand names Ozempic, Wegovy and Rybelsus
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.[17][18][19] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain.
Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin GLP-1, thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control. Side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.
Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The higher-dose formulation of semaglutide is indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity (initial body mass index (BMI) ≥ 30 kg/m2) or who are overweight (initial BMI ≥ 27 kg/m2) and have at least one weight-related comorbidity.
Semaglutide is dosed anywhere from .25 mg all the way up to 2mg a week. The injection is taken once weekly. Semaglutide works by increasing the production of insulin<https://en.m.wikipedia.org/wiki/Insulin>, the hormone that lowers the blood sugar level<https://en.m.wikipedia.org/wiki/Blood_sugar_level>. It also appears to enhance growth of pancreatic beta cells<https://en.m.wikipedia.org/wiki/Beta_cells>, which are responsible for insulin production and release. Additionally, it inhibits the production of glucagon<https://en.m.wikipedia.org/wiki/Glucagon>, the hormone that increases glycogenolysis<https://en.m.wikipedia.org/wiki/Glycogenolysis>(release of stored carbohydrate from the liver) and gluconeogenesis<https://en.m.wikipedia.org/wiki/Gluconeogenesis>(synthesis of new glucose). It reduces food intake by lowering appetite and slowing down digestion in the stomach, helping reduce body fat.
A review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery